Vericel (VCEL) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vericel (VCEL) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 17.3% versus a loss of 14.1%. Over five years, VRDN leads with a +7.4% price change compared with -21.1% for VCEL. Viridian Therapeutics is the larger company by market cap ($2.10 billion vs $2.08 billion), about 1.0 times the size.
Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VCEL | VRDN |
|---|---|---|
| Share price | $40.53 | $18.51 |
| Market cap | $2.08B | $2.10B |
| 1-day change | +1.20% | +0.91% |
| YTD return | +11.22% | -41.07% |
| 1-year return | +17.35% | -14.14% |
| 5-year return | -21.15% | +7.44% |
| P/E ratio (TTM) | 86.23 | — |
| Forward P/E | 47.91 | — |
| EPS (TTM) | $0.47 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.26M | $70.85M |
| Revenue growth (YoY) | +16.45% | +23359.93% |
| Net income (latest FY) | $16.52M | $-342.60M |
| Gross margin | 74.42% | — |
| Operating margin | 4.00% | -512.91% |
| Net margin | 5.98% | -483.57% |
| 52-week high | $49.32 | $34.29 |
| 52-week low | $28.95 | $13.18 |
| Distance from 52-week high | -17.82% | -46.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +49.44% | +98.57% |
| Average volume | 507.54K | 1.71M |
| Shares outstanding | 51.21M | 113.29M |
| Employees | 398 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed VRDN by 31.5 percentage points over the past year.
- Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +16.45%).
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
VCEL vs VRDN FAQ
Which is bigger, Vericel or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.10B compared with $2.08B for Vericel (VCEL).
Which stock has performed better over the past year, VCEL or VRDN?
VCEL returned +17.35% over the past 12 months, compared with -14.14% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Vericel and Viridian Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Vericel and Biotechnology: Pharmaceutical Preparations for Viridian Therapeutics.